The Question

Age-related retinal diseases, including macular degeneration, diabetic retinopathy, and glaucoma, contribute significantly to ocular decline. While a class of compounds known as geroprotectors has shown promise for systemic benefits related to cardiovascular and neurological aging, their specific effects on eye health remain largely uncharacterized. This lack of clarity creates challenges for clinicians seeking to integrate these agents into practice without compromising patient safety.

The Experiment

Researchers led by Nguyen at the Department of Ophthalmology undertook a comprehensive narrative review. This work synthesized reported therapeutic and adverse ocular outcomes across a range of geroprotective agents. The review specifically examined glucagon-like peptide-1 (GLP-1) receptor agonists, metformin, sodium-glucose cotransporter-2 inhibitors, statins, cannabinoids, calcium channel blockers, spermidine, taurine, nicotinamide adenine dinucleotide precursors, rapamycin, and mifepristone. The primary outcome variables assessed were the ocular effects, both beneficial and detrimental, associated with these agents.

What They Found

The synthesis of existing literature indicated that GLP-1 receptor agonists have been associated with a reduced risk of age-related glaucoma. However, the review also identified unconfirmed reports of severe nonarteritic anterior ischemic optic neuropathy linked to these same agents. Across the broader spectrum of geroprotective, metabolic, and weight-modifying therapies, the review highlighted similar uncertainties, noting that ocular effects remain incompletely characterized and variably reported, sometimes with controversial findings.

Why It Matters

Age-associated ocular decline involves converging patterns of neurodegeneration, microvascular injury, and chronic inflammation within the retina. This includes the loss of retinal ganglion cell axons and impaired microvascular circulation, which are key to conditions like glaucoma. The potential for geroprotectors to modulate these underlying mechanisms suggests avenues for optimizing ocular health. Characterizing these agents' precise impact could lead to strategies aimed at enhanced retinal ganglion cell survival, improved retinal microvascular perfusion, and reduced chronic ocular inflammation.

Study Limitations

As a narrative review, this study synthesizes existing data, which inherently means it is subject to the limitations of the original studies included, such as variability in methodologies, patient cohorts, and reporting standards. The abstract notes that some reported ocular effects are "unconfirmed" or "controversial," indicating a lack of consistent, high-certainty evidence in current literature. Furthermore, this review does not present new experimental data or direct measurements of therapeutic or adverse ocular outcomes.

Practical Application

It is too early to apply the findings regarding GLP-1 receptor agonists or other geroprotectors to a personal protocol for ocular health optimization. This review highlights areas of promising association, such as reduced glaucoma risk with GLP-1 receptor agonists, but also flags uncertainties and unconfirmed adverse reports. Before any specific recommendations for healthy adults can be made, large-scale, prospective randomized controlled trials are needed to confirm these findings, clarify specific mechanisms, and definitively establish the safety and efficacy of individual geroprotective agents, including precise dosing and duration, for ocular endpoints.

Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.

GLP-1 Receptor Agonists Lower Glaucoma Risk but May Pose Uncertain Optic Neuropathy Risk